EBIT (Quarterly)

EBIT: Income before interest and taxes.

BioXcel Therapeutics, Inc. (BTAI) had EBIT of $-10.19M for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$0.18M
Net Income	$-14.71M
Cost of Goods Sold	$0.02M
Gross Profit	$0.16M
Operating Expenses	$10.38M
Operating Income	$-10.19M
Non-Operating Income/Expense	$-4.52M
Pre-Tax Income	$-14.71M
Normalized Pre-Tax Income	$-14.71M
Income after Taxes	$-14.71M
Income from Continuous Operations	$-14.71M
Consolidated Net Income/Loss	$-14.71M
Normalized Income after Taxes	$-14.71M
EBIT	$-10.19M
EBITDA	$-10.18M
Weighted-Average Shares Outstanding (Basic)	30.30M
Weighted-Average Shares Outstanding (Diluted)	30.30M
Earnings per Share (EPS) (Basic)	$-0.49
Earnings per Share (EPS) (Diluted)	$-0.49
Balance Sheet Financials
Current Assets	$28.70M
Property, Plant, and Equipment	$0.10M
Long-Term Assets	$0.10M
Total Assets	$28.80M
Current Liabilities	$137.15M
Long-Term Debt	--
Long-Term Liabilities	$7.11M
Total Liabilities	$144.26M
Common Equity	$-115.46M
Tangible Shareholders Equity	$-115.46M
Shareholders Equity	$-115.46M
Common Shares Outstanding	31.30M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-17.91M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$2.95M
Beginning Cash	$28.76M
End Cash	$13.80M
Increase/Decrease in Cash	$-14.96M
Stock-Based Compensation	$0.79M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.21
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	-0.90
Gross Margin	87.91%
Operating Margin	-5600.55%
EBIT Margin	-5600.55%
EBITDA Margin	--
Pre-Tax Profit Margin	-8084.07%
Profit Margin	-8084.07%
Free Cash Flow	$-17.91M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.01
Inventory Turnover	0.05
Receiveable Turnover	2.22
Days Sales in Receivables	40.55
Return on Equity	12.74%
Return on Tangible Equity	12.74%
Return on Assets	-51.09%
Return on Investments	12.74%
Book Value Per Share	$-3.69
Free Cash Flow per Share	$-0.59
Operating Cash Flow per Share	$-0.59

Data from Zacks Investment Research, Inc.